Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Support Care Cancer. 2020 Jan 23;28(10):4761–4769. doi: 10.1007/s00520-020-05310-6

Table 3.1:

Summary of Sample Characteristics (n=180)

Emetogenicity
Highly-emetogenic (HEC) 127 (70.6%)
Moderately-emetogenic (MEC) 53 (29.4%)
Chemotherapy type
Carboplatin 12 (6.7%)
Cisplatin 34 (18.9%)
Dacarbazine 12 (6.7%)
Dactinomycin 21 (11.7%)
Other HEC 48 (26.7%)
MEC 53 (29.4%)
Cancer type
Solid tumor 73 (40.6%)
Lymphoma 48 (26.7%)
CNS 16 (8.9%)
Leukemia 43 (23.9%)
Cancer status
First occurrence 153 (85%)
Relapse 27 (15%)
HHS Vulnerability Disclosure